title: Ramosetron for the management of chemotherapy-induced gastrointestinal events in patients with hematological malignancies.
abstract: The objective of this study was to evaluate the efficacy and safety of ramosetron hydrochloride for the management of nausea and vomiting induced by chemotherapy in patients with hematological malignancies. A total of 30 patients with hematological malignancies were included in the ramosetron group. Ramosetron (0.3 mg i.v.) was administered 0.5 h before chemotherapy. The impact of ramosetron on anorexia, nausea and vomiting as well as other adverse effects were assessed. Meanwhile, another 39 patients received tropisetron (o.d. for 3 days). As compared to the tropisetron group, the response rate of the ramosetron group in controlling anorexia within 18-24 h after chemotherapy was higher (p < 0.05); within 18-24 h after chemotherapy, the complete response rate and effective rate in controlling nausea was higher (p < 0.05); within 12-18 h and 18-24 h after chemotherapy, the complete response rate and effective rate in controlling vomiting was higher (p < 0.05). The incidence of adverse effects was similar in both groups. We conclude that ramosetron belongs to a new generation of 5-HT3 receptor antagonists and that it is a safe, economic and effective antiemetic drug.
authors.affiliation: Department of Hematology, Rui-Jin Hospital, Shanghai Second Medical University, Shanghai, P.R. China.
authors.forename: X Y
authors.initials: XY
authors.lastname: Zeng
authors.forename: A H
authors.initials: AH
authors.lastname: Wang
authors.forename: Y F
authors.initials: YF
authors.lastname: Liu
authors.forename: Y
authors.initials: Y
authors.lastname: Chen
authors.forename: Y
authors.initials: Y
authors.lastname: Shen
authors.forename: Z X
authors.initials: ZX
authors.lastname: Shen
mesh_terms: D000293:Adolescent; D000328:Adult; D000368:Aged; D000932:Antiemetics / Q000627:therapeutic use*; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000009:adverse effects* / Q000627:therapeutic use; D001066:Appetite / Q000187:drug effects; D001562:Benzimidazoles / Q000627:therapeutic use*; D003248:Constipation / Q000139:chemically induced; D004244:Dizziness / Q000139:chemically induced; D064420:Drug-Related Side Effects and Adverse Reactions; D005260:Female; D005483:Flushing / Q000139:chemically induced; D005767:Gastrointestinal Diseases / Q000139:chemically induced / Q000188:drug therapy*; D006261:Headache / Q000139:chemically induced; D019337:Hematologic Neoplasms / Q000188:drug therapy*; D006801:Humans; D007211:Indoles / Q000627:therapeutic use; D008297:Male; D008875:Middle Aged; D009325:Nausea / Q000139:chemically induced / Q000517:prevention & control; D013894:Thirst / Q000187:drug effects; D016896:Treatment Outcome; D000077526:Tropisetron; D014839:Vomiting / Q000139:chemically induced / Q000517:prevention & control
chemical_list: D000932:Antiemetics; D001562:Benzimidazoles; D007211:Indoles; D000077526:Tropisetron; C071315:ramosetron